Archives rheumatoid-arthritis

in
Entry Author Date Location
Drug Discovery in Seattle 2015: An Updated History 08/03/15 Seattle
East Coast Biotech Roundup: Bluebird, Sarepta, Synlogic & More 05/22/15 Boston
AbbVie Snaps up Pharmacyclics, Pays Whopping $21B For Cancer Drug 03/05/15 National
With Celiac Deal, Celimmune Aims to Give New Life to Old Amgen Drug 03/02/15 New York
Vertex Buys Spine Drug on the QT As Part of Its Post-Hep C Makeover 02/20/15 Boston
Fannin Spinout Acelerox Aims to Halt Immune Attacks With Nanotech 02/11/15 Texas
Déjà Vu For Gilman as New Immunology Startup, Padlock, Gets $23M 12/18/14 Boston
West Coast Biotech Roundup: Amgen, Inslee, Fibrogen, Receptos & More 10/30/14 Seattle
Opsona, And Pharma Backers, Await Day of Reckoning for Kidney Drug 10/29/14 National
Bristol-Myers Kicks Arthritis Drug Back to Alder, Shares Tumble 09/02/14 Seattle
East Coast Biotech Roundup: Bluebird, Moderna, Navitor, & More 06/20/14 Boston
Biotech IPO Slump Deepens as Alder Prices Below Range 05/08/14 Seattle
East Coast Biotech Roundup: Proteon, Ataxion, NY Genome/Watson, & More 03/21/14 Boston
Alder BioPharmaceuticals Hits IPO Trail Looking for $115M 03/19/14 Seattle
Five Prime, Bristol-Myers Squibb Cut $350M Immuno-Oncology Deal 03/17/14 San Francisco
Get a Shot, Have Some Bread: ImmusanT’s Plan For a Celiac Vaccine 03/11/14 Boston
Molecular Diagnostics Are in a Rut. The Industry Needs the FDA 02/17/14 National
East Coast Biotech Roundup: Genocea, Eleven, NIH/Pharma, & More 02/07/14 Boston
Myriad Genetics Acquires Crescendo Bioscience for $270M 02/04/14 San Francisco
Fresh from IPO, Five Prime Advances Arthritis and Cancer Drugs 12/19/13 San Francisco
Bristol-Myers, Alder Drug for Rheumatoid Arthritis Passes Key Test 10/28/13 Seattle
Isis Ends Program, Still Has Options For Rheumatoid Arthritis Drug 08/05/13 San Diego
Using Frugal Business Model, Orphagen Targets Orphan Receptors 06/13/13 San Diego
San Diego Life Sciences Roundup: Effector, Ignyta, and More 05/23/13 San Diego
Big Data Is BS in Healthcare. When Will It Become Real? 04/15/13 National
Crescendo Bioscience Snags $28M For Arthritis Test 01/03/13 San Francisco
Innovimmune Pursues Pharma Partners, Shuns VCs 08/07/12 New York
Alder Biopharma Snags $38M To Charge Ahead With Antibody Drugs 04/19/12 Seattle
Abbott’s Humira, the 3rd-in-Class Drug That Toppled Lipitor as No. 1 04/16/12 National
Crescendo Bioscience Takes Arthritis Into the World of Hard Data 02/24/12 San Francisco
Page 1 of 4 next page »